FDA Brief

Warning letters Devices

FDA warning letter to

Opgal Optronic Industries Ltd.

High riskIssued Mar 4, 2021Posted Mar 4, 2021Center for Devices and Radiological Health

FDA warned Opgal Optronic Industries over unapproved Therm-App MD and MD Pro thermal cameras sold in U.S. with COVID-19 claims.

What happened

FDA reviewed Opgal's website on February 22 and 25, 2021, along with its YouTube, Twitter, and Facebook pages, and found the Therm-App MD and Therm-App MD Pro offered for measuring human body temperature and for sale in the United States. FDA says website and social media statements show the products are intended to help prevent the spread of COVID-19. FDA says the products were offered for sale without the required FDA approval, clearance, or authorization.

What FDA found

  1. FDA says the Therm-App MD and Therm-App MD Pro are medical devices because the company's website and social media say they help prevent the spread of COVID-19.

    section 201(h) of the Act, 21 U.S.C. § 321(h)
  2. The products were offered for sale in the United States without FDA marketing approval, clearance, or authorization.

    section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  3. The company did not notify FDA of its intent to introduce the products into interstate commerce, as required for premarket notification.

    section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)
  4. FDA says introducing these products into interstate commerce is prohibited.

    section 301(a), 21 U.S.C. § 331(a)
  5. FDA says temperature-screening devices can incorrectly detect normal or elevated body temperature, and the risk is higher when scanning multiple people at once.

  6. FDA cited website, brochure, video, and social media statements promoting the products as COVID-19 solutions or for preventing spread of the coronavirus.

What FDA wants

FDA asks Opgal to take immediate action to stop selling the products for COVID-19 and to email COVID-19-Task-Force-CDRH@fda.hhs.gov within 48 hours with the specific steps taken to address the violations, including documentation and how it will prevent recurrence. If it cannot act completely within 48 hours, it must state the reason and the time it will need.

Who should pay attention

  • distributors and resellers of thermal screening systems
  • U.S. buyers using temperature screening for COVID-19
  • medical device firms making COVID-19 claims on websites and social media

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk